EMD Chemicals, Inc. Launches First Bead-Based Multiplex Assays Using EpiTag™ Technology from Epitome Biosystems

Published: Feb 11, 2008

GIBBSTOWN, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--EMD Chemicals, Inc. (EMD), a subsidiary of Merck KGaA, Darmstadt, Germany, and Epitome Biosystems, Inc, announced today that EMD has launched WideScreen™ EpiTag™ ERK Pathway Assays, the first wave of bead-based, multiplex assays using EpiTag™ Technology licensed from Epitome Biosystems. The new line of assays will enable researchers to make quantitative, highly multiplexed measurements of important cell targets, greatly facilitating drug discovery efforts.

Back to news